CG
Carter Gould Cantor Fitzgerald Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$652B
| $727.21 | $825 |
13%
upside
| Overweight |
13 Aug ‘25
26 days ago |
|
2
Vertex Pharmaceuticals
VRTX
$102B
| $396.12 | $485 |
22%
upside
| Overweight |
5 Aug ‘25
1 month ago |
|
3
Amgen
AMGN
$153B
| $283.64 | $305 |
8%
upside
| Neutral |
24 Jun ‘25
2 months ago |
|
4
Bristol-Myers Squibb
BMY
$96B
| $47.14 | $55 |
17%
upside
| Neutral |
23 Apr ‘25
4 months ago |
|
5
Regeneron Pharmaceuticals
REGN
$60.8B
| $573.38 | $695 |
21%
upside
| Overweight |
22 Apr ‘25
4 months ago |
|
6
Pfizer
PFE
$141B
| $24.88 | $24 |
4%
downside
| Neutral |
22 Apr ‘25
4 months ago |
|
7
Merck
MRK
$212B
| $84.71 | $85 |
0%
upside
| Neutral |
22 Apr ‘25
4 months ago |
|
8
Gilead Sciences
GILD
$143B
| $115.05 | $125 |
9%
upside
| Overweight |
22 Apr ‘25
4 months ago |
|
9
AbbVie
ABBV
$375B
| $212.56 | $210 |
1%
downside
| Overweight |
22 Apr ‘25
4 months ago |
|
10
Neurocrine Biosciences
NBIX
$14.3B
| $144.10 | $165 |
15%
upside
| Overweight |
23 Dec ‘24
8 months ago |
|
|
11
Gilead Sciences
GILD
$143B
| $115.05 | $95 |
17%
downside
| Equal-Weight |
7 Nov ‘24
10 months ago |
|
|
12
Regeneron Pharmaceuticals
REGN
$60.8B
| $573.38 | $1,065 |
86%
upside
| Overweight |
1 Nov ‘24
10 months ago |
|
13
Travere Therapeutics
TVTX
$1.93B
| $21.64 | $20 |
8%
downside
| Overweight |
1 Nov ‘24
10 months ago |
|
|
14
Eli Lilly
LLY
$652B
| $727.21 | $975 |
34%
upside
| Overweight |
31 Oct ‘24
10 months ago |
|
15
Biogen
BIIB
$20.6B
| $140.67 | $180 |
28%
upside
| Equal-Weight |
31 Oct ‘24
10 months ago |
|
|
16
Bristol-Myers Squibb
BMY
$96B
| $47.14 | $43 |
9%
downside
| Underweight |
7 Oct ‘24
11 months ago |
|
|
17
Merck
MRK
$212B
| $84.71 | $140 |
65%
upside
| Overweight |
7 Oct ‘24
11 months ago |
|
|
18
Amgen
AMGN
$153B
| $283.64 | $315 |
11%
upside
| Equal-Weight |
7 Oct ‘24
11 months ago |
|
|
19
AbbVie
ABBV
$375B
| $212.56 | $212 |
0%
downside
| Overweight |
7 Oct ‘24
11 months ago |
|
20
Nuvalent
NUVL
$5.83B
| $80.89 | $100 |
24%
upside
| Overweight |
29 Aug ‘24
1 year ago |
|
21
Vor Biopharma
VOR
$248M
| $1.96 | $3 |
53%
upside
| Overweight |
14 Aug ‘24
1 year ago |
|
|
22
Pfizer
PFE
$141B
| $24.88 | $32 |
29%
upside
| Equal-Weight |
31 Jul ‘24
1 year ago |
|
|
BRNS
23
Barinthus Biotherapeutics
BRNS
$50.5M
| $1.24 | $3 |
142%
upside
| Overweight |
13 Jun ‘24
1 year ago |
|
24
Geron
GERN
$893M
| $1.40 | $9 |
543%
upside
| Overweight |
11 Jun ‘24
1 year ago |
|
25
Cytokinetics
CYTK
$6.34B
| $53.01 | $95 |
79%
upside
| Overweight |
23 May ‘24
1 year ago |
|